Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1975 Dec;11(6):555-9.
doi: 10.1007/BF01222106.

The contribution of endogenous insulin secretion to the ketogenic response to glucagon in man

The contribution of endogenous insulin secretion to the ketogenic response to glucagon in man

D S Schade et al. Diabetologia. 1975 Dec.

Abstract

The magnitude and direction of the lipolytic and ketogenic responses following exogenous glucagon administration is controversial and consideration of the possible role of endogenous insulin secretion upon these events has not been clarified. The present study examines the role of endogenous insulin secretion in modulating the net lipolytic and ketogenic activity of glucagon. Three groups characterized by different levels of endogenous insulin secretory capacity were studied. In all three groups, the responses in plasma insulin, betahydroxybutyrate, and free fatty acids were observed following bolus administration of 1.0 mug/kg glucagon. In the obese subjects with increased endogenous insulin secretion, glucagon administration resulted in a decline below basal levels of both free fatty acid and betahydroxybutyrate. In the diabetic subjects with no demonstrable endogenous insulin secretion, glucagon administration was followed by a rise in plasma free fatty acids and an exaggerated rise in plasma betahydroxybutyrate. The normal control group exhibited a response in betahydroxybutyrate midway between the obese and diabetic groups. These obwervations support the thesis that the magnitude of endogenous insulin secretion modulates the lipolytic and ketogenic actions of glucagon in man.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Lipid Res. 1972 Jul;13(4):483-90 - PubMed
    1. J Clin Invest. 1974 Oct;54(4):981-9 - PubMed
    1. J Clin Invest. 1970 Mar;49(3):537-47 - PubMed
    1. Diabetes. 1973 Aug;22(8):590-600 - PubMed
    1. J Clin Invest. 1974 Jan;53(1):190-7 - PubMed